Clinical Trial Update: Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of acalabrutinib, venetoclax, and obinutuzumab as initial therapy for chronic lymphocytic leukemia; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Gazyva (Obinutuzumab)
• Venclexta (venetoclax)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-12